Table 1.

Fasting anthropometric, endocrine, insulin, and glucose concentrations at baseline and postintervention treatment for 12 weeks with metformin, fish oil or fish oil-metformin in women with PCOS

Metformin
(n = 8)
Fish oil
(n = 13)
Fish oil-metformin
(n = 8)
Baseline
all groups
(n = 29)
BaselinePost (%)BaselinePost (%)BaselinePost (%)
Age, years25.0 ± 1.825.5 ± 1.228.7 ± 1.7
Body weight, kg109.8 ± 4.8117.9 ± 7.6116.1 ± 7.4 (-1)104.5 ± 5.7105.7 ± 5.6 (1)111.6 ± 10.3102.8 ± 7.8 (-8)
BMI, kg/m2
WC, cm
WHR
38.6 ± 1.4
45.7 ± 1.1
0.9 ± 0.01
41.9 ± 1.3
47.8 ± 2.3
0.9 ± 0.02
41.2 ± 0.9 (−1)
48.1 ± 2.3 (<1)
1.0 ± 0.03 (+10)
35.9 ± 1.8
43.8 ± 1.2
0.9 ± 0.02
36.4 ± 1.8 (1)
44.1 ± 1.3 (<1)
0.9 ± 0.02 (0)
40.5 ± 3.6
47.3 ± 2.5
0.9 ± 0.02
37.1 ± 2.3 (−8)
46.6 ± 2.0 (−1)
1.0 ± 0.02 (+10)
Fat mass, kg50.4 ± 2.856.3 ± 4.755.8 ± 4.5 (<1)46.6 ± 3.947.9 ± 4.5 (3)51.8 ± 6.444.8 ± 3.9 (−14)
Fat-free mass, kg
59.4 ± 1.661.3 ± 3.260.1 ± 3.4 (−2)58.2 ± 1.956.6 ± 2.3 (3)59.6 ± 4.358.2 ± 4.2 (−2)
Androstendione, nmol/L8.8 ± 0.77.2 ± 0.87.8 ± 1.8 (8.0)9.3 ± 0.911.1 ± 1.1 (16)9.6 ± 1.710.2 ± 0.1 (6)
Testosterone, nmol/L1.4 ± 0.11.3 ± 0.21.3 ± 0.4 (0)1.5 ± 0.21.6 ± 0.1 (6)1.4 ± 0.21.5 ± 0.2 (7)
Free T, pmol/L27.4 ± 2.823.8 ± 4.125.2 ± 8.1 (6)30.8 ± 6.034.7 ± 4.6 (13)26.8 ± 3.929.2 ± 2.3 (9)
SHBG, nmol/L34.4 ± 3.635.6 ± 6.055.6 ± 6.9 (36)39.0 ± 5.530.1 ± 4.9 (-22)29.3 ± 7.230.0 ± 6.3 (2)
FAI
DHEAS, μmol/L
4.7 ± 0.6
7.6 ± 0.6
4.4 ± 0.9
7.6 ± 1.2
5.1 ± 1.7 (16)
6.4 ± 1.2 (−16)
3.9 ± 0.9
8.2 ± 1.0
6.6 ± 0.9 (70)
8.4 ± 1.1 (2)
5.7 ± 1.2
6.7 ± 1.1
5.9 ± 0.9 (3)
7.25 ± 1.2 (8)
Insulin, pmol/L215.0 ± 28.0217.1 ± 46.4180.1 ± 52.2 (−17)223.4 ± 60.3181.1 ± 20.8 (−19)203.1 ± 43.7144.3 ± 19.0 (−29)
Glucose, mmol/L
OGTT (2-hr), mmol/L
4.9 ± 0.1
5.9 ± 0.2
4.8 ± 0.2
5.9 ± 0.4
4.7 ± 0.1 (-2)
6.4 ± 0.8 (8)
4.9 ± 0.1
6.0 ± 0.3
4.8 ± 0.2 (-2)
6.1 ± 0.5 (2)
4.9 ± 0.1
5.9 ± 1.2
4.6 ± 0.2 (−6)
5.7 ± 0.6 (−3)
HOMA-IR7.8 ± 1.17.9 ± 1.86.3 ± 1.9 (−20)8.1 ± 2.26.5 ± 0.8 (−20)7.4 ± 1.75.0 ± 0.8 (−32)
Metformin
(n = 8)
Fish oil
(n = 13)
Fish oil-metformin
(n = 8)
Baseline
all groups
(n = 29)
BaselinePost (%)BaselinePost (%)BaselinePost (%)
Age, years25.0 ± 1.825.5 ± 1.228.7 ± 1.7
Body weight, kg109.8 ± 4.8117.9 ± 7.6116.1 ± 7.4 (-1)104.5 ± 5.7105.7 ± 5.6 (1)111.6 ± 10.3102.8 ± 7.8 (-8)
BMI, kg/m2
WC, cm
WHR
38.6 ± 1.4
45.7 ± 1.1
0.9 ± 0.01
41.9 ± 1.3
47.8 ± 2.3
0.9 ± 0.02
41.2 ± 0.9 (−1)
48.1 ± 2.3 (<1)
1.0 ± 0.03 (+10)
35.9 ± 1.8
43.8 ± 1.2
0.9 ± 0.02
36.4 ± 1.8 (1)
44.1 ± 1.3 (<1)
0.9 ± 0.02 (0)
40.5 ± 3.6
47.3 ± 2.5
0.9 ± 0.02
37.1 ± 2.3 (−8)
46.6 ± 2.0 (−1)
1.0 ± 0.02 (+10)
Fat mass, kg50.4 ± 2.856.3 ± 4.755.8 ± 4.5 (<1)46.6 ± 3.947.9 ± 4.5 (3)51.8 ± 6.444.8 ± 3.9 (−14)
Fat-free mass, kg
59.4 ± 1.661.3 ± 3.260.1 ± 3.4 (−2)58.2 ± 1.956.6 ± 2.3 (3)59.6 ± 4.358.2 ± 4.2 (−2)
Androstendione, nmol/L8.8 ± 0.77.2 ± 0.87.8 ± 1.8 (8.0)9.3 ± 0.911.1 ± 1.1 (16)9.6 ± 1.710.2 ± 0.1 (6)
Testosterone, nmol/L1.4 ± 0.11.3 ± 0.21.3 ± 0.4 (0)1.5 ± 0.21.6 ± 0.1 (6)1.4 ± 0.21.5 ± 0.2 (7)
Free T, pmol/L27.4 ± 2.823.8 ± 4.125.2 ± 8.1 (6)30.8 ± 6.034.7 ± 4.6 (13)26.8 ± 3.929.2 ± 2.3 (9)
SHBG, nmol/L34.4 ± 3.635.6 ± 6.055.6 ± 6.9 (36)39.0 ± 5.530.1 ± 4.9 (-22)29.3 ± 7.230.0 ± 6.3 (2)
FAI
DHEAS, μmol/L
4.7 ± 0.6
7.6 ± 0.6
4.4 ± 0.9
7.6 ± 1.2
5.1 ± 1.7 (16)
6.4 ± 1.2 (−16)
3.9 ± 0.9
8.2 ± 1.0
6.6 ± 0.9 (70)
8.4 ± 1.1 (2)
5.7 ± 1.2
6.7 ± 1.1
5.9 ± 0.9 (3)
7.25 ± 1.2 (8)
Insulin, pmol/L215.0 ± 28.0217.1 ± 46.4180.1 ± 52.2 (−17)223.4 ± 60.3181.1 ± 20.8 (−19)203.1 ± 43.7144.3 ± 19.0 (−29)
Glucose, mmol/L
OGTT (2-hr), mmol/L
4.9 ± 0.1
5.9 ± 0.2
4.8 ± 0.2
5.9 ± 0.4
4.7 ± 0.1 (-2)
6.4 ± 0.8 (8)
4.9 ± 0.1
6.0 ± 0.3
4.8 ± 0.2 (-2)
6.1 ± 0.5 (2)
4.9 ± 0.1
5.9 ± 1.2
4.6 ± 0.2 (−6)
5.7 ± 0.6 (−3)
HOMA-IR7.8 ± 1.17.9 ± 1.86.3 ± 1.9 (−20)8.1 ± 2.26.5 ± 0.8 (−20)7.4 ± 1.75.0 ± 0.8 (−32)

Values are presented as mean ± SEM and variables were normally distributed. Post (%) represents mean percentage change from baseline within group.

Abbreviations: DHEAS, dehydroepiandrostendione; FAI, free androgen index; HOMA-IR, homeostatic model assessment of insulin resistance; OGTT (2-hr), oral glucose tolerance at 2 hours; SHBG, sex hormone binding globulin; T, testosterone; WC, waist circumference; WHR, waist hip ratio.

Table 1.

Fasting anthropometric, endocrine, insulin, and glucose concentrations at baseline and postintervention treatment for 12 weeks with metformin, fish oil or fish oil-metformin in women with PCOS

Metformin
(n = 8)
Fish oil
(n = 13)
Fish oil-metformin
(n = 8)
Baseline
all groups
(n = 29)
BaselinePost (%)BaselinePost (%)BaselinePost (%)
Age, years25.0 ± 1.825.5 ± 1.228.7 ± 1.7
Body weight, kg109.8 ± 4.8117.9 ± 7.6116.1 ± 7.4 (-1)104.5 ± 5.7105.7 ± 5.6 (1)111.6 ± 10.3102.8 ± 7.8 (-8)
BMI, kg/m2
WC, cm
WHR
38.6 ± 1.4
45.7 ± 1.1
0.9 ± 0.01
41.9 ± 1.3
47.8 ± 2.3
0.9 ± 0.02
41.2 ± 0.9 (−1)
48.1 ± 2.3 (<1)
1.0 ± 0.03 (+10)
35.9 ± 1.8
43.8 ± 1.2
0.9 ± 0.02
36.4 ± 1.8 (1)
44.1 ± 1.3 (<1)
0.9 ± 0.02 (0)
40.5 ± 3.6
47.3 ± 2.5
0.9 ± 0.02
37.1 ± 2.3 (−8)
46.6 ± 2.0 (−1)
1.0 ± 0.02 (+10)
Fat mass, kg50.4 ± 2.856.3 ± 4.755.8 ± 4.5 (<1)46.6 ± 3.947.9 ± 4.5 (3)51.8 ± 6.444.8 ± 3.9 (−14)
Fat-free mass, kg
59.4 ± 1.661.3 ± 3.260.1 ± 3.4 (−2)58.2 ± 1.956.6 ± 2.3 (3)59.6 ± 4.358.2 ± 4.2 (−2)
Androstendione, nmol/L8.8 ± 0.77.2 ± 0.87.8 ± 1.8 (8.0)9.3 ± 0.911.1 ± 1.1 (16)9.6 ± 1.710.2 ± 0.1 (6)
Testosterone, nmol/L1.4 ± 0.11.3 ± 0.21.3 ± 0.4 (0)1.5 ± 0.21.6 ± 0.1 (6)1.4 ± 0.21.5 ± 0.2 (7)
Free T, pmol/L27.4 ± 2.823.8 ± 4.125.2 ± 8.1 (6)30.8 ± 6.034.7 ± 4.6 (13)26.8 ± 3.929.2 ± 2.3 (9)
SHBG, nmol/L34.4 ± 3.635.6 ± 6.055.6 ± 6.9 (36)39.0 ± 5.530.1 ± 4.9 (-22)29.3 ± 7.230.0 ± 6.3 (2)
FAI
DHEAS, μmol/L
4.7 ± 0.6
7.6 ± 0.6
4.4 ± 0.9
7.6 ± 1.2
5.1 ± 1.7 (16)
6.4 ± 1.2 (−16)
3.9 ± 0.9
8.2 ± 1.0
6.6 ± 0.9 (70)
8.4 ± 1.1 (2)
5.7 ± 1.2
6.7 ± 1.1
5.9 ± 0.9 (3)
7.25 ± 1.2 (8)
Insulin, pmol/L215.0 ± 28.0217.1 ± 46.4180.1 ± 52.2 (−17)223.4 ± 60.3181.1 ± 20.8 (−19)203.1 ± 43.7144.3 ± 19.0 (−29)
Glucose, mmol/L
OGTT (2-hr), mmol/L
4.9 ± 0.1
5.9 ± 0.2
4.8 ± 0.2
5.9 ± 0.4
4.7 ± 0.1 (-2)
6.4 ± 0.8 (8)
4.9 ± 0.1
6.0 ± 0.3
4.8 ± 0.2 (-2)
6.1 ± 0.5 (2)
4.9 ± 0.1
5.9 ± 1.2
4.6 ± 0.2 (−6)
5.7 ± 0.6 (−3)
HOMA-IR7.8 ± 1.17.9 ± 1.86.3 ± 1.9 (−20)8.1 ± 2.26.5 ± 0.8 (−20)7.4 ± 1.75.0 ± 0.8 (−32)
Metformin
(n = 8)
Fish oil
(n = 13)
Fish oil-metformin
(n = 8)
Baseline
all groups
(n = 29)
BaselinePost (%)BaselinePost (%)BaselinePost (%)
Age, years25.0 ± 1.825.5 ± 1.228.7 ± 1.7
Body weight, kg109.8 ± 4.8117.9 ± 7.6116.1 ± 7.4 (-1)104.5 ± 5.7105.7 ± 5.6 (1)111.6 ± 10.3102.8 ± 7.8 (-8)
BMI, kg/m2
WC, cm
WHR
38.6 ± 1.4
45.7 ± 1.1
0.9 ± 0.01
41.9 ± 1.3
47.8 ± 2.3
0.9 ± 0.02
41.2 ± 0.9 (−1)
48.1 ± 2.3 (<1)
1.0 ± 0.03 (+10)
35.9 ± 1.8
43.8 ± 1.2
0.9 ± 0.02
36.4 ± 1.8 (1)
44.1 ± 1.3 (<1)
0.9 ± 0.02 (0)
40.5 ± 3.6
47.3 ± 2.5
0.9 ± 0.02
37.1 ± 2.3 (−8)
46.6 ± 2.0 (−1)
1.0 ± 0.02 (+10)
Fat mass, kg50.4 ± 2.856.3 ± 4.755.8 ± 4.5 (<1)46.6 ± 3.947.9 ± 4.5 (3)51.8 ± 6.444.8 ± 3.9 (−14)
Fat-free mass, kg
59.4 ± 1.661.3 ± 3.260.1 ± 3.4 (−2)58.2 ± 1.956.6 ± 2.3 (3)59.6 ± 4.358.2 ± 4.2 (−2)
Androstendione, nmol/L8.8 ± 0.77.2 ± 0.87.8 ± 1.8 (8.0)9.3 ± 0.911.1 ± 1.1 (16)9.6 ± 1.710.2 ± 0.1 (6)
Testosterone, nmol/L1.4 ± 0.11.3 ± 0.21.3 ± 0.4 (0)1.5 ± 0.21.6 ± 0.1 (6)1.4 ± 0.21.5 ± 0.2 (7)
Free T, pmol/L27.4 ± 2.823.8 ± 4.125.2 ± 8.1 (6)30.8 ± 6.034.7 ± 4.6 (13)26.8 ± 3.929.2 ± 2.3 (9)
SHBG, nmol/L34.4 ± 3.635.6 ± 6.055.6 ± 6.9 (36)39.0 ± 5.530.1 ± 4.9 (-22)29.3 ± 7.230.0 ± 6.3 (2)
FAI
DHEAS, μmol/L
4.7 ± 0.6
7.6 ± 0.6
4.4 ± 0.9
7.6 ± 1.2
5.1 ± 1.7 (16)
6.4 ± 1.2 (−16)
3.9 ± 0.9
8.2 ± 1.0
6.6 ± 0.9 (70)
8.4 ± 1.1 (2)
5.7 ± 1.2
6.7 ± 1.1
5.9 ± 0.9 (3)
7.25 ± 1.2 (8)
Insulin, pmol/L215.0 ± 28.0217.1 ± 46.4180.1 ± 52.2 (−17)223.4 ± 60.3181.1 ± 20.8 (−19)203.1 ± 43.7144.3 ± 19.0 (−29)
Glucose, mmol/L
OGTT (2-hr), mmol/L
4.9 ± 0.1
5.9 ± 0.2
4.8 ± 0.2
5.9 ± 0.4
4.7 ± 0.1 (-2)
6.4 ± 0.8 (8)
4.9 ± 0.1
6.0 ± 0.3
4.8 ± 0.2 (-2)
6.1 ± 0.5 (2)
4.9 ± 0.1
5.9 ± 1.2
4.6 ± 0.2 (−6)
5.7 ± 0.6 (−3)
HOMA-IR7.8 ± 1.17.9 ± 1.86.3 ± 1.9 (−20)8.1 ± 2.26.5 ± 0.8 (−20)7.4 ± 1.75.0 ± 0.8 (−32)

Values are presented as mean ± SEM and variables were normally distributed. Post (%) represents mean percentage change from baseline within group.

Abbreviations: DHEAS, dehydroepiandrostendione; FAI, free androgen index; HOMA-IR, homeostatic model assessment of insulin resistance; OGTT (2-hr), oral glucose tolerance at 2 hours; SHBG, sex hormone binding globulin; T, testosterone; WC, waist circumference; WHR, waist hip ratio.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close